Mirvetuxemab soravtansine is a well-tolerated [315] antibody–drug conjugate consisting of a mAb linked to an anti-mitotic agent, maytansinoid DM4, to target ovarian cancer cells expressing FRα. This evidence concerns the gene FOLR1 and ovarian carcinoma.